Tengion posts wider Q4 loss
Tengion, Inc. (TNGN: Quote), a clinical-stage regenerative medicine company, reported a fourth-quarter net loss of $14.0 million or $0.59 per share, wider than last year's net loss of $5.9 million or $0.48 per share.
Excluding items, adjusted net loss for the latest quarter was $6.2 million or $0.26 per share.
The company attributed the increase in the loss for the quarter mainly to an increase in research and development expense of $1.0 million related to preclinical studies associated with the company's Neo-Kidney Augment program.
This expense offset a $1.0 million decrease in depreciation expense related to a change in the estimated useful life of leasehold improvements at the Company's leased facility in Winston-Salem, North Carolina and the impairment of the property and equipment at the Company's leased facility in East Norriton, Pennsylvania.
Click here to receive FREE breaking news email alerts for Tengion, Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com